CoVisCollaborative Visualization
CoVisCommon Vlbi Interface Specification
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Alvogen and Covis Pharma have entered into an exclusive partnership and distribution agreement for the commercialization of Alvesco[R] (ciclesonide), a leading medicine for the treatment of persistent asthma.
United Kingdom-based AstraZeneca has completed sale of its rights to asthma drug Alvesco (ciclesonide) and nasal sprays Omnaris and Zetonna (ciclesonide) to Switzerland-based Covis Pharma, it was reported yesterday.
AstraZeneca Plc (LON:AZN), a global, science-led biopharmaceutical company, announced on Thursday the completion of an agreement with Covis Pharma B.V (Covis Pharma) to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated with rhinitis.
vulnificus infection had the highest hospitalization rate of 79% among all cases of vibrio according to COVIS, and they had the highest mortality rate of 18% (3).
Since the initiation of COVIS in 1988, 16 cases of toxigenic O141 have been reported in the United States.
(which was acquired by Teva from Allergan PLC in August for $40.5 billion), Lannett Co., Impax Laboratories Inc., Covis Pharma Holdings, Sun Pharmaceutical Industries Ltd., Mayne Pharma Group Ltd., the Par Pharmaceuticals Holdings subsidiary of Endo International PLC and Taro Pharmaceutical Industries Ltd., which is a unit of Sun Pharmaceutical.
In the United States, the Centers for Disease Control and Prevention's COVIS (Cholera and Other Vibrio Illness Surveillance) maintains a national database of vibriosis that contained detailed epidemiologic and transmission route information (12).
Companies Mentioned in this Report: MediQuest Therapeutics, Inc., Orion Oyj, Johnson & Johnson, Apricus Biosciences, Inc., Otsuka Holdings Co., Ltd., Forenap Pharma E.U.R.L., Actelion Ltd, Allergan Plc, Covis Pharmaceuticals, Inc., Bayer AG
Mitchell currently serves as executive chairman of the board of Covis Pharma Holdings S.a.r.l.
(TSX: CXR) (OTCQX: CHEHF) has completed the acquisition by the company of 18 products, being comprised of 12 branded products and five authorised generic contracts and a product distributed by a third party in Australia pursuant to the terms of a distribution agreement, from Luxembourg-based drugmaker Covis Pharma S.aI[euro].r.l and Covis Injectables, S.aI[euro].r.l for USD 1.2bn in cash, the company said on Tuesday.